Vebreltinib Receives Approval in China For MET Exon 14+ NSCLC
China’s National Medical Products Administration has granted conditional marketing approval to vebreltinib (APL-101; PBL-1001) for the treatment of patients with non–small cell lung cancer harboring MET exon 14 skipping mutations
Source: onclive.com